PATRICK Y. LAM, Ph.D.
Lam Drug Discovery Consulting, LLC
Medicinal chemistry and
drug discovery professional
Patrick Lam is currently amedicinal chemistry and drug discovery consultantat Lam Drug Discovery Consulting, LLC, Distinguished Professor of Chemistry at Baruch S. Blumberg Institute and Adjunct Professor at Drexel University College of Medicine. He recently retired from a director position in the Discovery Chemistry Department ofBristol-Myers Squibb Co.Patrick joined DuPont in 1984 and moved to BMS in 2001. In recent years, he has been involved with antivirals (HBV capsid, surface antigen and cccDNA inhibitors, Dengue Fever inhibitors, HIV-DCSIGN blockers), antithrombotics (FXIa and FXa inhibitors as anticoagulants; P2Y1 and PAR4 antagonists as antiplatelet agents), PCSK9 antisense oligonucleotide (ASO) therapeutics, prodrugs and carbohydrates. Patrick has >30 years of drug discovery experience. His expertise is ininnovationsin structure-based drug design, ADME, focused libraries, molecular recognition and nucleic acid therapeuticsto deliver biopharma clinical candidateswith novel profiles.
Patrick is responsible for a total of eight clinical candidates.He was the group leader/co-inventor responsible for the discovery ofEliquis®/Apixaban,a novel Factor Xa anticoagulant recently launched on the market. Eliquis®is projected by analysts to be a transformational medicine with “block-buster” sales potential. Eliquis®was recently chosen as the “Best New Medicine of 2012” by Med Ad News. He was the Medchem VP of Enantigen Therapeutics, specialized in HBV drug discovery, and contributed to the successful acquisition of Enantigen by Arbutus/Oncore Biopharma in 2014.
Patrick is internationally known as the co-discoverer of the powerfulChan-Lam Coupling Reaction. This is the copper-promoted oxidative coupling reaction for N/O-arylation with arylboronic acids and is complementaryto the Nobel-prize winning Suzuki-Miyaura Coupling Reaction.
Patrick has authored 98 papers/reviews/book chapters and is an inventor on 36 patents/patent applications. He has presented 110 invited seminars worldwide.Patrick has received numerous awards includingACS Heroes of Chemistry Award 2015for the discovery of Eliquis®; BMS Ondetti-Cushman Innovation Award for FXa inhibitor discovery in 2003; DuPont-Merck Summit Award for the discovery of cyclic ureas as HIV protease inhibitor capable of displacing the “structured water” in 1993. He serves on the Editorial Board of Current Medicinal Chemistry, Medicinal Chemistry, Letters in Drug Design & Discovery, Medicinal Research Reviews; Patrick was a member of Long Range Planning Committee of ACS Medicinal Chemistry Division (1997-2000).
Patrick received his Ph.D. from the University of Rochester (Dr. Louis Friedrich) and was a postdoctoral fellow in UCLA (Prof. Mike Jung and the late Prof. Don Cram, 1987 Nobel Laureate in chemistry).
